KAROŃ, Łukasz Mikołaj, ZYGMUNT, Anna, KAROŃ, Karolina, PEDRYCZ, Daria, DRAPAŁA, Grzegorz, GRABOWSKI, Wojciech and PEDRYCZ, Emilia. Targeting the Microbiome: The Role of Low-FODMAP Diet in Modulating Gut Health for IBS and Inflammatory Conditions. Journal of Education, Health and Sport. 2024;75:56153. eISSN 2391-8306.
https://dx.doi.org/10.12775/JEHS.2024.75.56153
https://apcz.umk.pl/JEHS/article/view/56153

The journal has had 40 points in Minister of Science and Higher Education of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of 05.01.2024 No. 32318. Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical culture sciences (Field of medical and health sciences); Health Sciences (Field of medical and health sciences).
Punkty Ministerialne 40 punktów. Załącznik do komunikatu Ministra Nauki i Szkolnictwa Wyższego z dnia 05.01.2024 Lp. 32318. Posiada Unikatowy Identyfikator Czasopisma: 201159. Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu).
The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 12.11.2024. Revised: 20.11.2024. Accepted: 27.11.2024. Published: 27.11.2024.

Targeting the Microbiome: The Role of Low-FODMAP Diet in Modulating Gut Health for IBS and Inflammatory Conditions

1. Karolina Karoń

- affiliation: Municipal Hospital in Zabrze

- ORCID: 0009-0005-0356-8907

2. Anna Zygmunt

- affiliation: Department of Pathology and Molecular Diagnostics, Medical University of Silesia in Katowice

- ORCID: 0009-0002-5849-6347

- corresponding author: e-mail: aniazygmunt82@gmail.com

3. Łukasz Karoń

- affiliation: Department of Pathology and Molecular Diagnostics, Medical University of Silesia in Katowice

- ORCID: 0009-0009-5083-8307

4. Daria Pedrycz

- affiliation: Department of Family Medicine, Medical University of Białystok

- ORCID: 0009-0001-4988-5992

5. Wojciech Grabowski

- affiliation: Municipal Hospital in Zabrze

- ORCID: 0009-0006-9238-1411

6. Grzegorz Drapała
- affiliation: Wojewódzki Szpital Zespolony w Kielcach
- ORCID: 0009-0008-1492-1544
7. Emilia Pedrycz
- affiliation: Wojewódzki Szpital Zespolony w Kielcach
- ORCID: 0009-0006-2751-2227

Key words: Low-FODMAP diet, Irritable bowel syndrome, Gastrointestinal symptom management, Gut microbiota modulation, Inflammatory bowel disease

Abstract

The Low-FODMAP diet has emerged as a key therapeutic intervention for managing irritable bowel syndrome (IBS), a prevalent gastrointestinal disorder characterized by recurrent abdominal pain and altered bowel habits. This study aims to evaluate the efficacy of the Low-FODMAP diet in alleviating IBS symptoms and to explore its potential as a broader therapeutic tool in other gastrointestinal disorders, including inflammatory conditions. Our review highlights significant improvements in symptom relief, notably in reducing bloating, pain, and bowel irregularities, which are commonly associated with IBS. The Low-FODMAP diet's mechanisms of action, involving modulation of gut microbiota and reduction of osmotic effects, provide new insights into its impact on gastrointestinal health.Our findings underscore the Low-FODMAP diet's potential applications beyond IBS, suggesting benefits in conditions such as inflammatory bowel disease (IBD) and small intestinal bacterial overgrowth (SIBO). However, the long-term impacts of this diet on gut microbiota composition, mental health, and immune function require further investigation. Future research should focus on these aspects, especially in relation to diet sustainability and microbial diversity. The clinical implications of this study encourage healthcare providers to consider the Low-FODMAP diet as a personalized, non-pharmacological option for gastrointestinal symptom management, with careful monitoring to ensure nutritional adequacy and individual patient needs.

Introduction

Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by recurrent abdominal pain and altered bowel habits, including diarrhea, constipation, or both . Affecting 5-20% of the global population, IBS significantly impacts patients' quality of life and has substantial economic consequences (1) . The exact etiology remains unknown, but potential triggers include diet, stress, poor sleep, and changes in gut bacteria. Diagnosis is based on clinical symptoms, as there is no definitive test for IBS (2). The Rome IV Criteria can be used to diagnose IBS (3). Treatment approaches are primarily symptomatic and may include lifestyle modifications, dietary changes, pharmacological interventions, and psychological support (4) Primary care physicians play a crucial role in managing IBS, emphasizing the importance of a strong doctor-patient relationship (5). The low FODMAP diet, which restricts fermentable oligosaccharides, disaccharides, monosaccharides, and polyols, has gained popularity as a treatment for irritable bowel syndrome (IBS) (6). This dietary approach aims to minimize intestinal distension caused by osmotic effects and bacterial fermentation of poorly absorbed short-chain carbohydrates (7). The diet's efficacy in alleviating IBS symptoms, particularly bloating and pain, has been demonstrated, although the quality of evidence varies. Potential mechanisms include modulation of visceral hypersensitivity, intestinal permeability, and microbiota changes (8). However, concerns exist regarding nutritional adequacy, microbiome alterations, and long-term effects (9). Implementation challenges include the need for professional guidance and individual response variations (8). Despite these limitations, the low FODMAP diet is considered a front-line therapy for IBS in many parts of the world (6).

The primary objective of this study is to assess the effectiveness of the Low-FODMAP diet in alleviating symptoms of irritable bowel syndrome (IBS) and to investigate its potential therapeutic applications in other gastrointestinal disorders, particularly those involving inflammatory conditions. This research aims to elucidate the mechanisms through which the Low-FODMAP diet modulates gut microbiota composition and function, thereby influencing gastrointestinal health outcomes. By expanding our understanding of the

diet's impact beyond IBS, we seek to explore its broader clinical utility and identify novel, evidence-based strategies for managing a spectrum of gut-related diseases.

The Low-FODMAP Approach: How It Works

What are FODMAPs?

FODMAPs, an acronym for Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols, are short-chain carbohydrates found in various foods that are often poorly absorbed in the small intestine (10). These compounds are characterized by their rapid fermentation by gut bacteria, a process that can lead to the production of gas and other gastrointestinal symptoms, such as bloating, flatulence, and abdominal pain, particularly in individuals with irritable bowel syndrome (IBS) (11). FODMAPs include several types of sugars and fibers: oligosaccharides (such as fructans and galacto-oligosaccharides), which cannot be digested due to the absence of necessary enzymes; disaccharides like lactose, which require the enzyme lactase for absorption; monosaccharides, particularly fructose, whose absorption depends on glucose presence and transporter efficiency; and polyols, sugar alcohols like sorbitol and mannitol, that have limited absorption across the intestinal barrier.(12; 13) Due to these absorption challenges, FODMAPs can contribute significantly to gastrointestinal discomfort in susceptible individuals, making their dietary management an important aspect of controlling IBS symptoms (14).

Principles and Mechanisms of the Low-FODMAP Diet

The low FODMAP diet restricts intake of fermentable oligo-, di-, mono-saccharides, and polyols - short-chain carbohydrates that are poorly absorbed in the small intestine (15; 9). This dietary approach aims to alleviate gastrointestinal symptoms like bloating, abdominal pain, and diarrhea in patients with irritable bowel syndrome (IBS) by minimizing intestinal distension caused by osmotic effects and bacterial fermentation. The diet involves avoiding high FODMAP foods and replacing them with low FODMAP alternatives, with long-term restrictions limited to symptom control (7). While evidence suggests positive impacts on IBS symptoms, concerns exist regarding nutritional adequacy and effects on the gut microbiome (9). Implementation requires detailed knowledge of food FODMAP content, with common high FODMAP sources in Asian cuisines including onion, garlic, legumes, and wheat-based products (16).

The low FODMAP diet (LFD) has emerged as a promising approach for managing irritable bowel syndrome (IBS) symptoms. FODMAPs are poorly absorbed short-chain carbohydrates that can cause osmotic effects and rapid fermentation in the intestine, potentially triggering gastrointestinal symptoms in IBS patients (17). Multiple studies have demonstrated the efficacy of LFD in reducing IBS symptoms and improving quality of life (18). The diet's mechanism of action involves modulating fecal fermentation, with decreased saccharolytic fermentation and increased proteolytic fermentation observed after LFD implementation (19). However, LFD may also reduce beneficial gut bacteria like bifidobacteria (Schumann et al., 2018). While short-term efficacy and safety of LFD have been established, long-term effects require further investigation (20).

The low FODMAP diet has emerged as an effective treatment for irritable bowel syndrome (IBS), with clinical response rates of 50-80%. Its mechanism of action involves reducing small intestinal water volume and colonic gas production, which can trigger symptoms in individuals with visceral hypersensitivity. The diet's efficacy has been demonstrated in multiple randomized controlled trials, showing improvements in bloating, flatulence, diarrhea, and global symptoms (21; 8). However, the low FODMAP diet also leads to significant changes in the gut microbiota and metabolome, the long-term effects of which are not yet fully understood. Additionally, the diet may impact intestinal permeability, immunity, and short-chain fatty acid production (21). While effective, the diet's implementation requires professional guidance and consideration of potential nutritional deficiencies and individual variations in response (23).

The Low-FODMAP Diet in IBS: Comparative Effectiveness and Patient-Centered Benefits

IBS Management Through Low-FODMAP

Recent systematic reviews and meta-analyses support the short-term efficacy of the low-FODMAP diet (LFD) in managing irritable bowel syndrome (IBS) symptoms. LFD has been shown to reduce gastrointestinal symptoms (24) and improve quality of life (20) compared to control diets. The diet's effectiveness is attributed to reduced colonic gas production and potential alterations in gastrointestinal epithelial integrity and microbiome composition (25). However, long-term effects and safety remain uncertain, with some studies reporting a significant reduction in luminal bifidobacteria (26). While LFD appears effective

in the short term for most IBS patients, supporting its use as first-line therapy (27), more long-term follow-up studies are needed to investigate potential adverse effects and nutritional adequacy (28).

Symptom Relief and Quality of Life: Patient Outcomes on Low-FODMAP

The low-FODMAP diet has been shown to significantly improve the quality of life for patients with irritable bowel syndrome (IBS) by reducing the frequency and severity of key symptoms, such as abdominal pain, bloating, diarrhea, and constipation. Numerous studies, including a meta-analysis by Altobelli et al., demonstrate that patients adhering to a low-FODMAP diet experience substantial symptom relief compared to those on traditional diets (29). Systematic reviews indicate that reductions in abdominal pain and bloating are particularly notable, with patients reporting enhanced daily functioning and comfort levels (24). Clinical trials further support these findings, showing that low-FODMAP interventions not only alleviate physical discomfort but also improve patients' psychological well-being by minimizing the unpredictability and distress associated with IBS symptoms (30). Comparisons with other dietary approaches have consistently revealed the superior efficacy of the low-FODMAP diet in reducing overall IBS symptom scores and enhancing quality of life indices (29). This growing body of evidence underscores the value of a structured low-FODMAP regimen as an effective, non-pharmacological strategy for managing IBS and improving patients' lives. (31).

Comparing Diet Therapies: Low-FODMAP Versus Other IBS Interventions

The Low-FODMAP diet has consistently demonstrated superiority in alleviating IBS symptoms compared to standard dietary interventions. Systematic reviews and meta-analyses reveal that the Low-FODMAP diet ranks highly in reducing abdominal pain, bloating, and bowel irregularities, offering a targeted approach for symptom relief in IBS patients (32). For instance, Black et al. reported that the Low-FODMAP diet significantly outperformed conventional dietary advice, such as that recommended by the British Dietetic Association, in terms of reducing abdominal bloating and improving stool consistency (33; 21). Furthermore, Altobelli et al. observed that patients on a Low-FODMAP diet experienced enhanced quality of life and symptom control compared to those following a traditional IBS diet, underscoring its clinical value as a non-pharmacological intervention (29). The Low-FODMAP diet’s efficacy is attributed to its unique ability to limit intake of fermentable carbohydrates, which

are known to increase intestinal water content and gas production, thus aggravating IBS symptoms in susceptible individuals. This targeted dietary approach offers a more personalized treatment for IBS compared to broader dietary guidelines, providing substantial benefits in managing symptoms and enhancing patients' daily functioning (34; 35).

Therapeutic Potential of Low-FODMAP Diet Beyond IBS: Inflammatory and Functional Gut Disorders

Exploring Low-FODMAP for IBD, Celiac, and Gut Dysfunctions

Emerging evidence suggests that the Low-FODMAP diet, widely recognized for its efficacy in managing irritable bowel syndrome (IBS), may also offer significant benefits for individuals with other gastrointestinal conditions, such as inflammatory bowel disease (IBD), celiac disease, and small intestinal bacterial overgrowth (SIBO). In IBD, where patients frequently experience IBS-like symptoms despite remission, studies have demonstrated that the Low-FODMAP diet can alleviate functional symptoms such as bloating, abdominal pain, and diarrhea, thereby enhancing quality of life without exacerbating inflammation (36). Meta-analyses have also supported the Low-FODMAP diet's role in symptom reduction for IBD patients in remission, highlighting a significant decrease in abdominal discomfort and bloating (37). Furthermore, for patients with celiac disease who continue to report IBS-like symptoms despite adherence to a gluten-free diet, the Low-FODMAP diet has shown promise in improving gastrointestinal symptoms and overall well-being. Studies indicate a notable reduction in abdominal pain and an improvement in mental health among celiac patients adopting a low-FODMAP regimen, even over a relatively short duration (38). For individuals with SIBO, the Low-FODMAP diet addresses symptoms linked to fermentation, offering relief from bloating, gas, and pain associated with bacterial overgrowth, as it reduces the intake of fermentable substrates that bacteria feed on, thus limiting symptom exacerbation (39). These findings underscore the potential of the Low-FODMAP diet as a therapeutic intervention across a spectrum of gut dysfunctions, warranting further investigation into its long-term effects and optimal implementation for diverse patient populations.

FODMAP Restriction in IBD: Reducing Inflammation, Enhancing Microbiota

Recent research indicates that the Low-FODMAP diet, traditionally used to alleviate IBS symptoms, may also benefit patients with inflammatory bowel disease (IBD) by reducing

functional gastrointestinal symptoms and potentially improving gut microbiota composition (10). Studies have demonstrated that FODMAP restriction can mitigate symptoms such as abdominal pain, bloating, and altered bowel habits, which frequently persist in IBD patients even during remission (40). While the diet does not directly address inflammation in IBD, reducing fermentable carbohydrates appears to decrease the osmotic load and gas production in the intestine, leading to symptomatic relief (41). Additionally, evidence suggests that the Low-FODMAP diet may influence microbiota composition, specifically by lowering levels of gas-producing bacteria that exacerbate symptoms. However, findings are mixed regarding its effects on inflammation markers, and further research is required to understand its impact on microbial diversity and inflammatory pathways in IBD (37). Despite these uncertainties, current meta-analyses and clinical trials provide support for FODMAP restriction as a supplementary dietary approach, especially for IBD patients suffering from IBS-like symptoms (42).

Low-FODMAP and SIBO: Current Insights and Symptom Relief

The low FODMAP diet has emerged as a promising treatment for irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO) symptoms. Multiple studies support its effectiveness in reducing global IBS symptoms in the short term. The diet's mechanism involves reducing colonic gas production, which may alleviate pain signaling (25). While the low FODMAP diet is widely recognized as a first-line therapy for IBS (43), its efficacy in SIBO treatment remains hypothetical and requires further research (44). Implementation of the diet should be guided by dietitians to ensure proper nutrition and minimize potential drawbacks (45). Long-term effectiveness and personalization of the diet have shown promise, with at least 50% of individuals experiencing symptom relief (46).

Gut Microbiota and the Low-FODMAP Diet: Impacts on Diversity, Metabolites, and Immune Interactions

Microbial Diversity Under Low-FODMAP: Gains and Losses

Research on the low FODMAP diet's impact on gut microbiota in IBS patients reveals complex effects. While the diet reduces symptoms, it also alters the colonic kupa microenvironment, leading to higher fecal pH and reduced total bacterial abundance (47). Consistently, studies show a decrease in Bifidobacteria abundance on the low FODMAP diet

(48; 49). However, effects on overall microbial diversity and short-chain fatty acid concentrations remain inconclusive (49). Interestingly, two distinct microbiota subtypes in IBS patients have been identified: IBSP (pathogenic-like) and IBSH (health-like). The IBSP subtype shows greater clinical responsiveness to the low FODMAP diet, with microbiota shifting towards a healthier profile (50). These findings suggest that microbiota signatures could potentially guide personalized IBS treatment. However, the long-term implications of reduced FODMAP intake on gut health require further investigation (51).

Short-Chain Fatty Acids and Gut Health: Low-FODMAP's Metabolic Impact

Short-chain fatty acids (SCFAs), primarily acetate, propionate, and butyrate, are produced by gut microbiota through fermentation of dietary fiber and play crucial roles in maintaining gut and metabolic health (52; 53). SCFAs contribute to gut integrity, regulate appetite and energy expenditure, and improve glucose homeostasis (52). They act as signaling molecules via G-protein coupled receptors and as epigenetic regulators by inhibiting histone deacetylase (53). SCFAs have been linked to reduced risk of obesity, type 2 diabetes, and cardiovascular disease (54). In irritable bowel syndrome patients, higher abundance of methane and SCFA metabolism pathways in the gut microbiome predicts better response to a low-FODMAP diet (55). While animal studies show promising results, more well-controlled human studies are needed to fully understand the metabolic consequences of elevated gut-derived SCFA production (56).

Microbiota as a Mediator: Immune Interactions on a Low-FODMAP Diet

Recent studies have explored the role of microbiota in mediating the effects of a low-FODMAP diet on irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Research indicates that a low-FODMAP diet can significantly improve gut symptoms and quality of life in patients with IBS and quiescent IBD (57; 58). This dietary intervention alters the gut microbiome composition, particularly reducing the abundance of beneficial bacteria like Bifidobacterium adolescent and Faecalibacterium prausnitzii (59). The diet-induced changes in microbiota regulate intestinal expression of inflammatory and neuro-muscular gene sets, potentially mediating the diet's beneficial effects (60). Furthermore, the low-FODMAP diet may restore gut endocrine cell density, which is typically low in IBS patients, by influencing gut bacteria and their fermentation by-products (61).

Challenges of the Low-FODMAP Diet: Nutritional Deficits, Individualization, and Long-Term Considerations

Nutrient Trade-Offs: Fiber and Essential Nutrient Limitations on Low-FODMAP

The low FODMAP diet has gained popularity for treating irritable bowel syndrome (IBS), but concerns about its nutritional adequacy have been raised (9). Studies show that IBS patients often fail to meet dietary reference values for multiple nutrients, particularly fiber (62). While a 4-week low FODMAP diet does not significantly impact most nutrient intakes or diet diversity when supervised by a dietitian, it may decrease overall diet quality (63). Some micronutrient decreases were observed in low FODMAP diets compared to control diets, but most differences disappeared after adjusting for energy intake (64). Potential limitations of the low FODMAP diet include nutritional adequacy, cost, and difficulty in teaching and maintaining the diet. However, many of these concerns can be addressed with the involvement of a skilled nutritionist who can ensure nutritional adequacy and compliance (65).

Personalization Matters: Specialist Supervision to Minimize Diet Risks

The low FODMAP diet is an effective treatment for irritable bowel syndrome (IBS) symptoms, consisting of three phases: restriction, reintroduction, and personalization (32). While beneficial, concerns have been raised about potential nutritional deficits and alterations to gut microbiome composition from long-term FODMAP restriction (66). To mitigate these risks, specialist supervision by a dietitian is crucial throughout the diet implementation process (67). Dietitians play a vital role in patient assessment, providing tailored dietary counseling, and monitoring progress across multiple appointments (8). The importance of professional guidance is underscored by a reported case of severe weight loss and malnutrition following unsupervised adherence to a strict low FODMAP diet (68). This case highlights the potential dangers of extreme dietary restriction without proper supervision and emphasizes the need for personalized, dietitian-guided approaches to ensure both symptom relief and nutritional adequacy (69).

Long-Term Effects of Low-FODMAP: Mental Health and Quality of Life Insights

Long-term adherence to a low-FODMAP diet (LFD) for irritable bowel syndrome (IBS) management shows promising results. Studies report significant improvements in

gastrointestinal symptoms, quality of life, anxiety, depression, and fatigue over periods ranging from 6 months to 2 years (70; 71; 72; 73). Adherence rates vary between 50-82%, with higher adherence correlating to better symptom relief (74). Despite challenges in following the diet, particularly when eating out or traveling, patient satisfaction remains high at 70-89% (75). Nutritional adequacy is generally maintained, although one study noted decreased short-chain fatty acids (76). The diet's long-term effectiveness is further supported by improvements in bowel habits and disease course (77). However, some studies highlight difficulties in adherence and acceptability over time (70), suggesting the need for ongoing support and education for IBS patients following an LFD.

Conclusion

This review highlights the Low-FODMAP diet's efficacy in managing irritable bowel syndrome (IBS), underscoring its role as a first-line dietary intervention that can significantly improve quality of life for individuals with functional gastrointestinal disorders. Through mechanisms involving reduced fermentation, decreased osmotic effects, and modulation of visceral hypersensitivity, the Low-FODMAP diet effectively alleviates key IBS symptoms such as bloating, abdominal pain, and altered bowel habits. Emerging evidence suggests that this dietary approach may also benefit patients with other gastrointestinal conditions, including inflammatory bowel disease (IBD) and small intestinal bacterial overgrowth (SIBO), though further exploration is warranted to understand its broader therapeutic potential.The Low-FODMAP diet’s application in gastroenterology represents a promising shift toward patient-centered, non-pharmacological management strategies for chronic gut disorders. By targeting fermentable carbohydrates, this approach provides a targeted pathway for symptom relief, offering a personalized method for managing digestive discomfort where pharmacological options are limited or ineffective. However, the diet's impact on long-term gut health, particularly concerning the gut microbiota and its metabolic outputs, raises important questions about sustained use and potential microbial imbalances. As such, the therapeutic role of the Low-FODMAP diet in gastroenterology continues to evolve, meriting further clinical validation and refinement. Future research should prioritize longitudinal studies to assess the diet's long-term effects on the microbiome and metabolic health, particularly regarding mental health implications and immune interactions. Advanced investigation into the diet’s effects on patients with inflammatory conditions like IBD is also necessary, as these populations could benefit from adjunct dietary interventions tailored to

their unique pathophysiological needs. Understanding these dynamics will be crucial for optimizing the Low-FODMAP diet's application across a broader spectrum of gut-related conditions. For clinicians and dietitians, the successful implementation of the Low-FODMAP diet requires individualized care and ongoing monitoring to ensure nutritional adequacy and mitigate potential drawbacks. Professional guidance is essential to personalize the diet to each patient's tolerance and health status, ensuring both symptom relief and a balanced dietary intake. By adhering to these principles, healthcare providers can enhance the Low-FODMAP diet's efficacy while safeguarding against adverse nutritional outcomes, ultimately supporting a more holistic approach to gastrointestinal health management.

Disclosure

Author's contribution: Karolina Karoń, Anna Zygmunt, Łukasz Karoń, Daria Pedrycz Wojciech Grabowski, Grzegorz Drapała, Emilia Pedrycz
Conceptualisation: Karolina Karoń, Anna Zygmunt, Łukasz Karoń, Daria Pedrycz
Methodology: Karolina Karoń, Anna Zygmunt, Wojciech Grabowski
Software: Karolina Karoń, Emilia Pedrycz, Grzegorz Drapała
Check: Karolina Karoń, Anna Zygmunt, Emilia Pedrycz
Formal: Karolina Karoń, Łukasz Karoń, Wojciech Grabowski, Emilia Pedrycz
Investigation: Karolina Karoń, Anna Zygmunt, Łukasz Karoń, Wojciech Grabowski, Daria Pedrycz
Resources: Karolina Karoń, Łukasz Karoń, Wojciech Grabowski, Grzegorz Drapała
Data curation: Karolina Karoń, Anna Zygmunt, Łukasz Karoń, Wojciech Grabowski
Writing - Rough Preparation: Karolina Karoń, Daria Katarzyna Pedrycz
Writing - Review and Editing: Karolina Karoń, Łukasz Karoń, Emilia Pedrycz
Visualisation: Karolina Karoń, Łukasz Karoń, Wojciech Grabowski, Grzegorz Drapała
Supervision: Karolina Karoń, Łukasz Karoń, Wojciech Grabowski, Grzegorz Drapała
Project Administration: Karolina Karoń, Łukasz Karoń, Emilia Pedrycz

All authors have read and agreed with the published version of the manuscript.

Funding statement: The study did not receive special funding.
Institutional review board statement: Not applicable.

Informed consent statement: Not applicable.

Data availability statement: Not applicable.

Conflict of interest: The authors declare no conflict of interest.

Bibliography:

1. Domingo JJS. Síndrome del intestino irritable. *Medicina Clínica*. 2021;158(2):76-81. doi:10.1016/j.medcli.2021.04.029
2. Ford AC, Moayyedi P, Chey WD, et al. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. *The American Journal of Gastroenterology*. 2018;113:1-18. doi:10.1038/s41395-018-0084-x
3. Tan Z, Tan Y, Lin H, How C. Irritable bowel syndrome: an approach for primary care physicians. *Singapore Medical Journal*. 2022;63(7):367. doi:10.4103/0037-5675.354224
4. Preston K, Krumian R, Hattner J, De Montigny D, Stewart M, Gaddam S. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. *Beneficial Microbes*. 2018;9(5):697-706. doi:10.3920/bm2017.0105
5. Di Palma JA, Herrera JL. The role of Effective Clinician-Patient Communication in the management of irritable bowel syndrome and chronic constipation. *Journal of Clinical Gastroenterology*. 2012;46(9):748-751. doi:10.1097/mcg.0b013e31825a2ff2
6. Gibson PR. History of the low FODMAP diet. *Journal of Gastroenterology and Hepatology*. 2017;32(S1):5-7. doi:10.1111/jgh.13685
7. Iacovou M, Tan V, Muir JG, Gibson PR. The low FODMAP diet and its application in East and Southeast Asia. *Journal of Neurogastroenterology and Motility*. 2015;21(4):459-470. doi:10.5056/jnm15111
8. Bertin L, Zanconato M, Crepaldi M, et al. The role of the FODMAP diet in IBS. *Nutrients*. 2024;16(3):370. doi:10.3390/nu16030370
9. Catassi G, Lionetti E, Gatti S, Catassi C. The low FODMAP diet: many question marks for a catchy acronym. *Nutrients*. 2017;9(3):292. doi:10.3390/nu9030292

10. Galgano F, Mele MC, Tolve R, et al. Strategies for Producing Low FODMAPs foodstuffs: Challenges and Perspectives. *Foods*. 2023;12(4):856. doi:10.3390/foods12040856
11. Ammoury R, Gupta S. Colic and gastrointestinal gas. In: *Elsevier eBooks*. ; 2010:119-126.e3. doi:10.1016/b978-1-4377-0774-8.10011-9
12. Dominici S, Marescotti F, Sanmartin C, et al. Lactose: Characteristics, Food and Drug-Related Applications, and Its Possible Substitutions in Meeting the Needs of People with Lactose Intolerance. *Foods*. 2022;11(10):1486. doi:10.3390/foods11101486
13. Sanders LM. Carbohydrate: digestion, absorption and metabolism. In: *Elsevier eBooks*. ; 2015:643-650. doi:10.1016/b978-0-12-384947-2.00114-8
14. Vakil N. Dietary fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) and gastrointestinal disease. *Nutrition in Clinical Practice*. 2018;33(4):468-475. doi:10.1002/ncp.10108
15. Marciniak M, Cwynar ES, Wiśniewski P, Dobrowolska A. Możliwość zastosowania diety FODMAP w leczeniu zaburzeń żołądkowo-jelitowych u sportowców. *Kosmos*. 2023;72(1):63-70. doi:10.36921/kos.2023_2915
16. [Low Fermentable Oligo-, Di- and Monosaccharides and Polyols (FODMAP) diet in the treatment of patients with irritable bowel syndrome: basic principles and methodology]. *PubMed*. 2021;89(6):38-47. doi:10.24411/0042-8833-2020-10077
17. Shepherd SJ, Lomer MCE, Gibson PR. Short-Chain carbohydrates and functional gastrointestinal disorders. *The American Journal of Gastroenterology*. 2013;108(5):707-717. doi:10.1038/ajg.2013.96
18. Esmaillzadeh A, Pourmand H. Consumption of a low fermentable Oligo-, Di-, Mono-saccharides, and polyols diet and irritable bowel syndrome: A systematic review. *International Journal of Preventive Medicine*. 2017;8(1):104. doi:10.4103/ijpvm.ijpvm_175_17
19. Valeur J, Røseth AG, Knudsen T, et al. Fecal fermentation in irritable bowel syndrome: influence of dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols. *Digestion*. 2016;94(1):50-56. doi:10.1159/000448280
20. Schumann D, Klose P, Lauche R, Dobos G, Langhorst J, Cramer H. Low fermentable, oligo-, di-, mono-saccharides and polyol diet in the treatment of irritable bowel

syndrome: A systematic review and meta-analysis. *Nutrition*. 2017;45:24-31. doi:10.1016/j.nut.2017.07.004

21. Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. *Gut*. 2017;66(8):1517-1527. doi:10.1136/gutjnl-2017-313750
22. Eswaran S. Low FODMAP in 2017: Lessons learned from clinical trials and mechanistic studies. *Neurogastroenterology & Motility*. 2017;29(4). doi:10.1111/nmo.13055
23. Tuck CJ, Vanner SJ. Dietary therapies for functional bowel symptoms: Recent advances, challenges, and future directions. *Neurogastroenterology & Motility*. 2017;30(1). doi:10.1111/nmo.13238
24. Van Lanen AS, De Bree A, Greyling A. Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis. *European Journal of Nutrition*. Published online February 14, 2021. doi:10.1007/s00394-020-02473-0
25. Whelan K, Staudacher H. Low FODMAP diet in irritable bowel syndrome: a review of recent clinical trials and meta-analyses. *Current Opinion in Clinical Nutrition & Metabolic Care*. 2022;25(5):341-347. doi:10.1097/mco.0000000000000854
26. Tuck CJ, Muir JG, Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols: role in irritable bowel syndrome. *Expert Review of Gastroenterology & Hepatology*. 2014;8(7):819-834. doi:10.1586/17474124.2014.917956
27. Bellini M, Tonarelli S, Nagy A, et al. Low FODMAP diet: Evidence, doubts, and hopes. *Nutrients*. 2020;12(1):148. doi:10.3390/nu12010148
28. Liu ZS, Lin CF, Chen PW. Transcriptome analysis of Lactobacillus rhamnosus GG strain treated with prebiotic - bovine lactoferrin under a cold environment. *Journal of Food and Drug Analysis*. 2021;29(3):402-418. doi:10.38212/2224-6614.3369
29. Altobelli E, Del Negro V, Angeletti P, Latella G. Low-FODMAP diet improves irritable bowel syndrome symptoms: A Meta-Analysis. *Nutrients*. 2017;9(9):940. doi:10.3390/nu9090940
30. Yoon SR, Lee JH, Lee JH, et al. Low-FODMAP formula improves diarrhea and nutritional status in hospitalized patients receiving enteral nutrition: a randomized, multicenter, double-blind clinical trial. *Nutrition Journal*. 2015;14(1). doi:10.1186/s12937-015-0106-0

31. Eswaran S, Farida JP, Green J, Miller JD, Chey WD. Nutrition in the management of gastrointestinal diseases and disorders: the evidence for the low FODMAP diet. *Current Opinion in Pharmacology*. 2017;37:151-157. doi:10.1016/j.coph.2017.10.008
32. Whelan K, Martin LD, Staudacher HM, Lomer MCE. The low FODMAP diet in the management of irritable bowel syndrome: an evidence-based review of FODMAP restriction, reintroduction and personalisation in clinical practice. *Journal of Human Nutrition and Dietetics*. 2018;31(2):239-255. doi:10.1111/jhn.12530
33. Black CJ, Staudacher HM, Ford AC. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. *Gut*. 2021;71(6):1117-1126. doi:10.1136/gutjnl-2021-325214
34. Riezzo G, Prospero L, Orlando A, et al. A Tritordeum-Based Diet for Female Patients with Diarrhea-Predominant Irritable Bowel Syndrome: Effects on Abdominal Bloating and Psychological Symptoms. *Nutrients*. 2023;15(6):1361. doi:10.3390/nu15061361
35. Okawa Y. A Discussion of Whether Various Lifestyle Changes can Alleviate the Symptoms of Irritable Bowel Syndrome. *Healthcare*. 2022;10(10):2011. doi:10.3390/healthcare10102011
36. Pedersen N, Ankersen DV, Felding M, et al. Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease. *World Journal of Gastroenterology*. 2017;23(18):3356. doi:10.3748/wjg.v23.i18.3356
37. Zhan YL, Zhan YA, Dai SX. Is a low FODMAP diet beneficial for patients with inflammatory bowel disease? A meta-analysis and systematic review. *Clinical Nutrition*. 2017;37(1):123-129. doi:10.1016/j.clnu.2017.05.019
38. Roncoroni L, Bascuñán KA, Doneda L, et al. A low FODMAP Gluten-Free diet improves functional gastrointestinal disorders and overall mental health of celiac disease patients: a randomized controlled trial. *Nutrients*. 2018;10(8):1023. doi:10.3390/nu10081023
39. Testa A, Imperatore N, Rispo A, et al. Beyond irritable bowel syndrome: the efficacy of the low FODMAP diet for improving symptoms in inflammatory bowel diseases and celiac disease. *Digestive Diseases*. 2018;36(4):271-280. doi:10.1159/000489487
40. Prince AC, Myers CE, Joyce T, Irving P, Lomer M, Whelan K. Fermentable Carbohydrate Restriction (Low FODMAP Diet) in Clinical Practice Improves Functional Gastrointestinal Symptoms in Patients with Inflammatory Bowel

Disease. *Inflammatory Bowel Diseases*. 2016;22(5):1129-1136. doi:10.1097/mib.0000000000000708

41. Simões CD, Maganinho M, Sousa AS. FODMAPs, inflammatory bowel disease and gut microbiota: updated overview on the current evidence. *European Journal of Nutrition*. 2022;61(3):1187-1198. doi:10.1007/s00394-021-02755-1
42. Gibson PR. Use of the low-FODMAP diet in inflammatory bowel disease. *Journal of Gastroenterology and Hepatology*. 2017;32(S1):40-42. doi:10.1111/jgh.13695
43. Ireton-Jones C. The low FODMAP diet. *Current Opinion in Clinical Nutrition & Metabolic Care*. 2017;20(5):414-419. doi:10.1097/mco.0000000000000398
44. Litwiniuk M, Zaniuk M, Hurkała K, et al. Treatment of small intestinal bacterial overgrowth: Conventional antibiotic therapy and alternative therapy - probiotics and low FODMAP diet. *Journal of Education Health and Sport*. 2023;41(1):57-69. doi:10.12775/jehs.2023.41.01.005
45. Roszkowska P, Klimczak E, Ostrycharz E, et al. Small Intestinal Bacterial Overgrowth (SIBO) and Twelve Groups of Related Diseases—Current state of knowledge. *Biomedicines*. 2024;12(5):1030. doi:10.3390/biomedicines12051030
46. Wielgosz-Grochowska JP, Domanski N, Drywień ME. Efficacy of an irritable bowel syndrome diet in the treatment of small intestinal bacterial overgrowth: a Narrative review. *Nutrients*. 2022;14(16):3382. doi:10.3390/nu14163382
47. Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. *Gut*. 2014;64(1):93-100. doi:10.1136/gutjnl-2014-307264
48. Vandeputte D, Joossens M. Effects of Low and High FODMAP Diets on Human Gastrointestinal Microbiota Composition in Adults with Intestinal Diseases: A Systematic Review. *Microorganisms*. 2020;8(11):1638. doi:10.3390/microorganisms8111638
49. So D, Loughman A, Staudacher HM. Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: a systematic review with meta-analysis. *American Journal of Clinical Nutrition*. 2022;116(4):943-952. doi:10.1093/ajcn/nqac176
50. Vervier K, Moss S, Kumar N, et al. Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet. *Gut*. 2021;71(9):1821-1830. doi:10.1136/gutjnl-2021-325177

51. Staudacher HM, Scholz M, Lomer MCe, et al. Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probiotics. *Clinical Nutrition*. 2020;40(4):1861-1870. doi:10.1016/j.clnu.2020.10.013
52. Blaak EE, Canfora EE, Theis S, et al. Short chain fatty acids in human gut and metabolic health. *Beneficial Microbes*. 2020;11(5):411-455. doi:10.3920/bm2020.0057
53. Kasubuchi M, Hasegawa S, Hiramatsu T, Ichimura A, Kimura I. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. *Nutrients*. 2015;7(4):2839-2849. doi:10.3390/nu7042839
54. Chambers ES, Preston T, Frost G, Morrison DJ. Role of gut Microbiota-Generated Short-Chain fatty acids in metabolic and cardiovascular health. *Current Nutrition Reports*. 2018;7(4):198-206. doi:10.1007/s13668-018-0248-8
55. Eetemadi A, Tagkopoulos I. Methane and fatty acid metabolism pathways are predictive of Low-FODMAP diet efficacy for patients with irritable bowel syndrome. *Clinical Nutrition*. 2021;40(6):4414-4421. doi:10.1016/j.clnu.2020.12.041
56. Calvigioni M, Bertolini A, Codini S, et al. HPLC-MS-MS quantification of short-chain fatty acids actively secreted by probiotic strains. *Frontiers in Microbiology*. 2023;14. doi:10.3389/fmicb.2023.1124144
57. Cox SR, Lindsay JO, Fromentin S, et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. *Gastroenterology*. 2019;158(1):176-188.e7. doi:10.1053/j.gastro.2019.09.024
58. El-Salhy M, Hatlebakk JG, Hausken T. Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. *Nutrients*. 2019;11(8):1824. doi:10.3390/nu11081824
59. Pearl A, Bootz H, Melzer E, et al. Diet-induced modifications to human microbiome reshape colonic homeostasis in irritable bowel syndrome. *bioRxiv (Cold Spring Harbor Laboratory)*. Published online August 15, 2021. doi:10.1101/2021.08.15.456374
60. Bootz-Maoz H, Pearl A, Melzer E, et al. Diet-induced modifications to human microbiome reshape colonic homeostasis in irritable bowel syndrome. *Cell Reports*. 2022;41(7):111657. doi:10.1016/j.celrep.2022.111657

61. Haenel H. D. Burkitt: Gesund leben mit Ballaststoffen. Ein Beitrag zur Verhinderung vieler Zivilisationskrankheiten. 124 Seiten, 46 Abb. Hippokrates Verlag, Stuttgart 1982. Preis: 14,80 DM. *Nahrung/Food*. 1983;27(1):94. doi:10.1002/food.19830270127
62. Staudacher HM, Ralph FSE, Irving PM, Whelan K, Lomer MCE. Nutrient intake, diet quality, and diet diversity in irritable bowel syndrome and the impact of the low FODMAP diet. *Journal of the Academy of Nutrition and Dietetics*. 2019;120(4):535-547. doi:10.1016/j.jand.2019.01.017
63. Erenstein O, Poole N, Donovan J. Role of staple cereals in human nutrition: Separating the wheat from the chaff in the infodemics age. *Trends in Food Science & Technology*. 2021;119:508-513. doi:10.1016/j.tifs.2021.11.033
64. Eswaran S, Dolan RD, Ball SC, Jackson K, Chey W. The Impact of a 4-Week Low-FODMAP and mNICE Diet on Nutrient Intake in a Sample of US Adults with Irritable Bowel Syndrome with Diarrhea. *Journal of the Academy of Nutrition and Dietetics*. 2019;120(4):641-649. doi:10.1016/j.jand.2019.03.003
65. Di Nardo G, Barbara G, Borrelli O, et al. Italian guidelines for the management of irritable bowel syndrome in children and adolescents. *the Italian Journal of Pediatrics/Italian Journal of Pediatrics*. 2024;50(1). doi:10.1186/s13052-024-01607-y
66. De Palma G, Bercik P. Long-term personalized low FODMAP diet in IBS. *Neurogastroenterology & Motility*. 2022;34(4). doi:10.1111/nmo.14356
67. Fernandes M, De Almeida MR, Costa V, Dieta PC, Restrita D, Fodmaps E. Papel do nutricionista numa dieta restrita em FODMAPs. *Acta Portuguesa De Nutrição*. 2020;23. doi:10.21011/apn.2020.2310
68. Trott N, Aziz I, Rej A, Sanders DS. How Patients with IBS Use Low FODMAP Dietary Information Provided by General Practitioners and Gastroenterologists: A Qualitative Study. *Nutrients*. 2019;11(6):1313. doi:10.3390/nu11061313
69. Ke TJ, Sameeha MJ, Siah KTH, Jeffri PBQB, Idrus NAB, Krishnasamy S. Practices and barriers in implementing the low FODMAP diet for irritable bowel Syndrome among Malaysian dietitians: a Qualitative study. *Nutrients*. 2024;16(21):3596. doi:10.3390/nu16213596
70. Weynants A, Goossens L, Genetello M, De Looze D, Van Winckel M. The long-term effect and adherence of a low fermentable oligosaccharides disaccharides monosaccharides and polyols (FODMAP) diet in patients with irritable bowel

syndrome. *Journal of Human Nutrition and Dietetics*. 2019;33(2):159-169. doi:10.1111/jhn.12706

71. Kortlever TL, Huinink STB, Offereins M, et al. Low-FODMAP diet is associated with improved quality of life in IBS Patients—A Prospective observational study. *Nutrition in Clinical Practice*. 2019;34(4):623-630. doi:10.1002/ncp.10233
72. Bellini M, Tonarelli S, Barracca F, et al. A Low-FODMAP Diet for Irritable Bowel Syndrome: Some Answers to the Doubts from a Long-Term Follow-Up. *Nutrients*. 2020;12(8):2360. doi:10.3390/nu12082360
73. Bardacke JA, Yarrow L, Rosenkranz SK. The Long-Term effects of a Low–Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet for irritable bowel syndrome management. *Current Developments in Nutrition*. 2023;7(10):101997. doi:10.1016/j.cdnut.2023.101997
74. Ribichini E, Scalese G, Mocci C, Severi C. Gut–Brain Axis and Psychopathology: Exploring the Impact of Diet with a Focus on the Low-FODMAP Approach. *Nutrients*. 2024;16(20):3515. doi:10.3390/nu16203515
75. Prospero L, Riezzo G, Linsalata M, Orlando A, D'Attoma B, Russo F. Psychological and Gastrointestinal Symptoms of Patients with Irritable Bowel Syndrome Undergoing a Low-FODMAP Diet: The Role of the Intestinal Barrier. *Nutrients*. 2021;13(7):2469. doi:10.3390/nu13072469
76. Lambiase C, Rossi A, Morganti R, et al. Adapted Low-FODMAP Diet in IBS Patients with and without Fibromyalgia: Long-Term Adherence and Outcomes. *Nutrients*. 2024;16(19):3419. doi:10.3390/nu16193419
77. Morariu ID, Avasilcai L, Vieriu M, et al. Effects of a Low-FODMAP diet on Irritable Bowel Syndrome in Both Children and Adults—A Narrative Review. *Nutrients*. 2023;15(10):2295. doi:10.3390/nu15102295